EXHALE-2 - Asthma Study Sponsor and Protocol Number: Areteia Therapeutics, Inc / AR-DEX-22-01 Specialty: Pulmonology Type: Investigational Drug Inclusion: Age > 18 with a diagnosis of asthma Minimum daily treatment of medium-high dose asthma controller medication (for at least one year)≥2 exacerbations in past 12 months (steroid or hospitalization)